PROFILE |
 |
Biofield is going to give it another go. After all but ceasing operations, the company will try again to develop and market its Biofield Diagnostic System, which employs single-use sensors to detect and examine changes associated with breast cancer. The system, which is not yet approved by the FDA, is based on the belief that epithelial cancers are characterized by changes in the electrical charge of the affected tissue; the sensors analyze these changes and identify if a lesion is malignant or benign. The process requires less than 20 minutes, and has possible applications to cancers of the ovaries, skin, prostate, and colon. Chairman and CEO David Long and his family own more than half of Biofield.
COMPETITION |
 |
EPIX Medical, Inc. (EPIX)
OmniCorder Technologies, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.00
Employees: 3
Revenue per employee: $0.00
KEY PEOPLE |
 |
David M. Long, Jr.
CEO
CONTACT INFO |
 |
1025 Nine North Dr.
Alpharetta, GA 30004
US
Phone: 770-740-8180
Fax: 770-740-9366
|